



ImmunoCellular
Investor Relations Department
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States

Visit IR website [↗](#)

AMEX: IMUC

Last Trade:	0.31
Trade Time:	3:59 PM ET November 22, 2017
Change:	-0.03 ↓ (9.118%)
Day Range	0.30 - 0.32
52-Week Range	0.25 - 4.27
Volume	3,316,553

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

November 22, 2017

[ImmunoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017](#)

November 21, 2017

[ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results](#)

November 17, 2017

[ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017](#)

October 3, 2017

[ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET](#)

September 13, 2017

[ImmunoCellular Therapeutics Announces NYSE MKT Acceptance of its Plan of Compliance](#)

Financials [\[View all \]](#)

March 9, 2017

[Annual Report \(10-K\)](#)

April 28, 2017

[Proxy Statement \(DEF 14A\)](#)

November 21, 2017

[Quarterly Report \(10-Q\)](#)

August 14, 2017

[Quarterly Report \(10-Q\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)